NA
LENZ

NewEdge Advisors’s LENZ Therapeutics LENZ Stock Holding History

NewEdge Advisors’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$625 Hold
110
– – ﹤0.01% 4042
2026
Q1 		$1.01K Hold
110
– – ﹤0.01% 3905
2025
Q4 		$1.76K Hold
110
– – ﹤0.01% 3907
2025
Q3 		$5.13K Buy
+110
New +$4.04K ﹤0.01% 3526

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
7IH
72 Investment Holdings Stamford, Connecticut $50M AUM 647.58% 1-Year Est. Return

NewEdge Advisors's LENZ Position: Q2 2026 in Review

NewEdge Advisors held its LENZ Therapeutics (LENZ) position steady in Q2 2026 at 110 shares worth $625. The position accounts for ﹤0.01% of the portfolio, ranked #4042.

NewEdge Advisors first reported a position in LENZ in Q3 2025 and has held it in 4 quarters since. The position peaked at $5.13K in Q3 2025. 144 funds tracked by Wall St. Rank hold LENZ as of Q2 2026.

  • NewEdge Advisors held 110 shares of LENZ Therapeutics worth $625 as of Q2 2026.
  • NewEdge Advisors left its LENZ Therapeutics share count unchanged in Q2 2026.
  • LENZ Therapeutics made up ﹤0.01% of NewEdge Advisors's portfolio in Q2 2026, its #4042 holding.
  • NewEdge Advisors first reported a position in LENZ Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • NewEdge Advisors's LENZ Therapeutics position peaked at $5.13K in Q3 2025.
  • 144 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.